Atacicept met its Phase 3 proteinuria reduction endpoint, supporting optimism for Vera's accelerated FDA approval filing ...

Atrasentan (Vanrafia) was approved in 2025 for the treatment of IgAN in people who are at risk of their disease getting worse quickly. It belongs to a class of medicines called endothelin receptor ...

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Novartis’ Vanrafia, a treatment aimed at decreasing proteinuria in adults with primary immunoglobulin A nephropathy ...

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

The drug, known as atrasentan and sold as Vanrafia, blocks a specific protein in the kidneys known as endothelin A (ETA) receptor, which causes inflammation and cellular damage leading to proteinuria.

Novartis stock popped Thursday — prompting rival Travere Therapeutics to slide — after winning Food and Drug Administration approval for a kidney disease treatment. Late Wednesday, the FDA ...

Basel, April 3, 2025 – Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia ® (atrasentan), a potent and selective endothelin A (ETA ...